Literature DB >> 12729829

3D QSAR studies of the interaction between beta-tubulin and microtubule stabilizing antimitotic agents (MSAA). A combined pharmacophore generation and pseudoreceptor modeling approach applied to taxanes and epothilones.

Fabrizio Manetti1, Stefano Forli, Laura Maccari, Federico Corelli, Maurizio Botta.   

Abstract

Based on the conformer of paclitaxel extracted from the experimental tubulin structure, a pharmacophoric model has been generated and used to find the chemical features common to the taxane and epothilone classes of compounds. This original alignment has been translated into the experimental tubulin binding site obtaining an assembly subsequently submitted to the pseudoreceptor modeling approach. As a result, an original 3D QSAR model, able to evaluate, at a quantitative level, the relationships between the molecular structures and biological data of the studied compounds, has been obtained.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12729829     DOI: 10.1016/s0014-827x(03)00052-1

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  4 in total

Review 1.  Epothilones: From discovery to clinical trials.

Authors:  Stefano Forli
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

2.  Design, synthesis and biological evaluation of bridged epothilone D analogues.

Authors:  Qiao-Hong Chen; Thota Ganesh; Peggy Brodie; Carla Slebodnick; Yi Jiang; Abhijit Banerjee; Susan Bane; James P Snyder; David G I Kingston
Journal:  Org Biomol Chem       Date:  2008-11-06       Impact factor: 3.876

3.  De(side chain) model of epothilone: bioconformer interconversions DFT study.

Authors:  Danuta Rusinska-Roszak; Marek Lozynski
Journal:  J Mol Model       Date:  2009-01-20       Impact factor: 1.810

4.  Synthesis and Biological Evaluation of 7-Deoxy-Epothilone Analogues.

Authors:  Laura M Woods; Joseph W Arico; Jeffrey D Frein; Dan L Sackett; Richard E Taylor
Journal:  Int J Mol Sci       Date:  2017-03-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.